Bristol Myers Squibb announced a major strategic agreement with Anthropic today. The pharmaceutical leader will deploy Claude across its global business operations. This rollout serves as a new Shared Intelligence Platform for the company. The enterprise deployment will empower more than 30,000 global employees.
The deal combines deep scientific expertise with frontier artificial intelligence. Both companies want to accelerate the discovery of transformational medicines. Furthermore, the strategy moves past basic conversational chatbots. The system brings advanced reasoning into day-to-day corporate workflows.
Advancing Biopharma Workflows With Agentic AI
The deployment targets research, clinical development, manufacturing, and commercial divisions. First, data science teams will use Claude Code. This tool speeds up software and AI development. Next, researchers will apply AI reasoning to proprietary molecular and clinical data. This helps target identification in oncology, hematology, neuroscience, and immunology.
Additionally, the tool automates complex clinical trial documentation. The system drafts clinical study reports and safety narratives. In manufacturing, the platform aids root-cause investigations and batch release decisions. This system maintains full enterprise governance and audit controls.
The collaboration builds on three years of digital investments. BMS uses a multi-vendor strategy for its internal platform.
“For more than 160 years, BMS has pushed the boundaries of science to transform patients’ lives, and artificial intelligence is the single most powerful opportunity we have to accelerate that mission today,” said Greg Meyers, EVP and Chief Digital & Technology Officer, Bristol Myers Squibb. “Most enterprise AI stops at the chatbot. The real prize is the untapped value still trapped behind decades of data silos, and this collaboration is how we reach it. Anthropic’s Claude gives us the agentic capabilities, pace of innovation, and security necessary to connect our systems and put that collective knowledge in the hands of every BMS employee to accelerate innovation for patients. The companies that lead the next decade of biopharma will be the ones that learn to operate fundamentally differently with AI, and BMS intends to be one of them.”
The platform safely connects to thousands of internal data repositories. This integration creates a secure, centralized knowledge layer.
“By giving employees access to Claude’s agentic capabilities, connected to thousands of data sources across the company. BMS is creating a single intelligence layer that can generate a clinical study report from underlying trial data, surface the right scientific context from decades of internal research, or trace the root cause of a manufacturing deviation in real time,” said Eric Kauderer-Abrams, Head of Life Sciences, Anthropic. “In a regulated global enterprise, that means medicines reach patients faster, with BMS’s scientific depth and operational rigor accelerated by Claude agents at every step.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
